Recent 8-K filings for NTRB

• April 7, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA

  Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.

• February 13, 2026, 6:59 PM ET other material materiality 0.70 negative item 7.01item 9.01

  Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default

  Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.

• February 3, 2026, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Nutriband shareholders approve preferred share increase from 10M to 20M; two new directors appointed

  Shareholders approved amendment to increase authorized preferred shares from 10,000,000 to 20,000,000 with 86.25% of votes cast in favor.

• December 30, 2025, 6:59 PM ET M&A materiality 0.75 positive item 7.01item 9.01

  Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%

  Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

• October 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)

  FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.

• September 3, 2025, 7:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Nutriband discloses option/warrant exercises from Feb-Jul 2025 totaling 845K shares

  Stock options exercised on 20,055 shares for $44,206 total exercise price.

• August 7, 2025, 7:59 PM ET other material materiality 0.55 neutral item 3.02item 5.03item 9.01 ◈ Governance Changes

  Nutriband issues Series A Preferred stock dividend of 3,008,643 shares to common holders

  Stock dividend of Series A Preferred Stock: 1 share for every 4 common shares, issued Aug 5, 2025.

• July 16, 2025, 7:59 PM ET dividend materiality 0.55 neutral item 5.03item 9.01 ◈ Governance Changes

  Nutriband declares Series A Convertible Preferred stock dividend; record date July 25, 2025

  Board authorized 2,788,678 shares of Series A Convertible Preferred Stock (non-voting).

• April 9, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Nutriband signs Associate Partnership with MLS team Charlotte FC

  Agreement with Charlotte FC (Major League Soccer) to build brand visibility.

• February 13, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

  Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.

• February 12, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent

  Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.

• January 29, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07

  Nutriband stockholders elect directors, approve auditor and stock plan at 2025 annual meeting

  All seven director nominees elected with ~99% of votes cast; each received over 7.4M for votes.

• December 30, 2024, 6:59 PM ET regulatory materiality 0.50 positive item 7.01item 9.01

  Nutriband extends AVERSA patent to Macao; now covered in 46 countries

  Macao IP Office assigned patent number J/9010 with entry date December 17, 2024.

• October 31, 2024, 7:59 PM ET regulatory materiality 0.55 positive item 7.01item 9.01

  Nutriband receives Chinese patent for AVERSA abuse-deterrent transdermal system

  CNIPA fully issued Patent No. ZL 202211158031 for 'Abuse and Misuse Deterrent Transdermal System' related to AVERSA technology.

• September 18, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline

  Share buyback program authorizes repurchase of up to $1,000,000 of common stock.

• June 3, 2024, 7:59 PM ET other materiality 0.20 neutral item 3.02item 9.01

  Nutriband amends 8-K to disclose warrants omitted from prior conversion filing

  Amendment adds 152,460 warrants to purchase common stock at $6.43 per share, expiring May 14, 2029.

• May 21, 2024, 7:59 PM ET other material materiality 0.45 neutral item 3.02item 9.01

  Nutriband converts $300K debt into 76,230 shares at $4.00 per share

  Converted $300,000 principal plus $4,921.79 accrued interest on a Creditline Promissory Note.

• May 17, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Nutriband appoints Sergei Glinka as director effective May 15, 2024

  Appointed Sergei Glinka as a director effective May 15, 2024.

• April 23, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband raises $8.4M in Regulation S equity offering of units with warrants

  Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.

• March 28, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 3.02item 8.01item 9.01

  Nutriband grants stock options to CEO, President, CFO, COO, CSO and amends stock plan

  Item 3.02: Unregistered sales of options to purchase 97,500 shares each to CEO Gareth Sheridan and President Serguei Melnik at $2.61/share.

• January 25, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Nutriband stockholders elect six directors, ratify auditor, approve say on pay, choose 1-year frequency

  All six director nominees elected: Sheridan, Melnik, Hamilton, Bujoreanu, Mancas, Gram each with >5.2M votes for.

• January 11, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

  Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.

• December 29, 2023, 6:59 PM ET other material materiality 0.55 neutral item 3.02item 9.01

  Nutriband converts $2M note into 1.03M shares at $2.00/share

  Holder TII Jet Services LDA converted $2M principal plus $53,440 accrued interest into 1,026,720 common shares at $2.00/share.

Executive changes

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

9 positive 1 negative 13 neutral

source · NTRB on sec.gov